A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

To evaluate the safety and tolerability of multiple, ascending doses of PF-04958242 administered orally to psychiatrically stable subjects with schizophrenia receiving antipsychotic and adjunctive medication.

This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.

Inclusion Criteria:

• Psychiatrically stable subjects with schizophrenia
• Evidence of stable schizophrenia symptomatology ≥ 3 months
• Score on MCCB Letter-number span + Spatial span subtest < 40.

Exclusion Criteria:

• History of seizures or of a condition with risk of seizures
• History of abnormal EEG.
• Pregnant or nursing females, and women of child bearing potential